NCT06072781Phase 3Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-10-15Estimated

Enrollment · participants270Estimated

Source updated2026-08-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Low Grade Serous Ovarian Cancer

Treatments or interventions studied

avutometinibDrugAlso known as avutometinib (VS-6766)
DefactinibDrugAlso known as defactinib (VS-6063)
Pegylated liposomal doxorubicinDrugAlso known as Caelyx, Doxil, Lipodox
PaclitaxelDrugAlso known as Nov-Onxol, Onxol, Navaplus, Taxol
LetrozoleDrugAlso known as Femara
AnastrozoleDrugAlso known as Arimidex

Primary outcomes · main study measures

measure: Progression Free Survival (PFS) per blinded independent central review (BICR); description: Progression-free survival (PFS) according to RECIST version 1.1, per blinded independent central review (BICR); timeFrame: Up to 24 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history